Genome Therapeutics Corp. was an early biotech company. It was founded in 1961 by Orrie M. Friedman under the name Collaborative Research Inc.[1] Under the leadership of Helen Donis-Keller and using internal funds, the company produced one of the first linkage maps of the whole human genome in the mid-1980s.[2][3]
The name was later changed its name to Genome Therapeutics. In 1994, it produced the first commercial genome sequence,[2] that of Helicobacter pylori, the pathogen responsible for peptic ulcers. The rights to the genome were sold to Astra AB of Sweden for $22 million and a similar deal struck with Schering-Plough.[2] In addition to infectious agents, it also worked on heritable diseases including asthma.[4]
In 2004, Genome Therapeutics changed its name to Oscient Pharmaceuticals[5] and its sequencing division joined with Agencourt Bioscience. The latter spun out Agencourt Personal Genomics which was acquired by ABI for $120 million in 2007.[6]
References
edit- ^ "Dr. Orrie M. Friedman, 94, biotech pioneer". Boston Globe. July 1, 2009.
- ^ a b c "Capitalizing on the genome". 13. May 1996: 1.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Cook-Deegan, Robert (1996). The Gene Wars: Science, Politics and the Human Genome. ISBN 9780393313994.
- ^ "Waltham firm lands $67m deal Genome Therapeutics expands asthma venture". HighBeam Research. December 24, 1996. Archived from the original on November 2, 2012.
- ^ "Genome Therapeutics Changes Name to Oscient Pharmaceuticals Corporation to Reflect Focus on Drug Development and Commercialization". April 13, 2004.
- ^ "For ABI, Developing Agencourt's Sequencing Technology Is a High Priority". GenomeWed Daily News. 6 June 2006.